Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Acquires $1,536,844.54 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the stock in a transaction on Tuesday, June 16th. The stock was acquired at an average cost of $24.98 per share, for a total transaction of $1,536,844.54. Following the acquisition, the insider owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, June 15th, Ra Capital Management, L.P. acquired 6,146 shares of Hemab Therapeutics stock. The shares were acquired at an average cost of $24.89 per share, with a total value of $152,973.94.
• On Wednesday, May 20th, Ra Capital Management, L.P. acquired 996 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.94 per share, for a total transaction of $24,840.24.
• On Tuesday, May 19th, Ra Capital Management, L.P. bought 3,802 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.97 per share, for a total transaction of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.90 per share, with a total value of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.98 per share, for a total transaction of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Stock Performance

Shares of COAG stock opened at $29.24 on Friday. Hemab Therapeutics Holdings, Inc. has a 12-month low of $23.00 and a 12-month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on COAG shares. Wedbush assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $42.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target for the company. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Finally, HC Wainwright assumed coverage on Hemab Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $40.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.40.

Key Stories Impacting Hemab Therapeutics

Here are the key news stories impacting Hemab Therapeutics this week:

• Positive Sentiment: HC Wainwright began coverage of Hemab Therapeutics with a Buy rating and a $40 price target, signaling analyst confidence in the company’s longer-term upside. Article Title
• Positive Sentiment: Ra Capital Management, Hemab’s major shareholder, continued adding to its stake with multiple purchases, including 61,523 shares and 6,146 shares, which can be read as a strong insider vote of confidence. Article Title
• Neutral Sentiment: HC Wainwright’s earnings estimates for 2026 through 2030 remain deeply negative, indicating Hemab is still expected to post significant losses as it remains a clinical-stage biotech company. Article Title
• Neutral Sentiment: Several comparison and analyst update articles on Hemab and peer Prime Medicine were published, but they do not appear to introduce new company-specific operational news. Article Title

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.